Sort   by:  
 Page size 
To validate the suitability of two commonly used colorectal cancer cell lines, DLD1 and SW480, as model systems to study colorectal carcinogenesis, we treated these cell lines with beta-catenin siRNA and identified beta-catenin target genes using DNA microarrays. The list of identified target genes ...
ORGANISM(S): Homo sapiens 
Employing Cre/loxP technology, a mouse model of liver specific Cdh1 (E-cadherin) depletion was created (fl/fl | +/wt). Previously, the mice had already been compared to littermates with normal Ecadherin levels (fl/fl | wt/wt), using a broad range of laboratory methods (Serum parameters, long-term we...
ORGANISM(S): Mus musculus 
Resistance formation is one of the major hurdles in cancer therapy. Metronomic anti-angiogenic treatment of xenografted prostate cancer tumors in SCID mice with cyclophosphamide (CPA) results in the appearance of resistant tumors. To investigate the complex molecular changes occurring during resista...
ORGANISM(S): Homo sapiens 
Gastric cancer is still one of the most common causes of cancer-related death worldwide, which is mainly attributable to late diagnosis and poor treatment options. Infection with H. pylori, different environmental factors and genetic alterations are known to influence the risk of developing gastric ...
ORGANISM(S): Homo sapiens 
Duchenne muscular dystrophy (DMD) is caused by mutations in the X-linked dystrophin (DMD) gene. The absence of dystrophin protein leads to progressive muscle weakness and wasting, disability and death. To establish a tailored large animal model of DMD, we deleted DMD exon 52 in male pig cells by gen...
ORGANISM(S): Sus scrofa 
LC-MS/MS based investigation of protein abundance changes, induced by DZNep treatment in A549-ACE2 cell line (0.75 uM DZNep, vehicle PBS; 6h pre-treatment, harvested 24 h.p.i. with mock/SARS-CoV/SARS-CoV-2 at MOI 3) or primary human bronchial epithelial cells (NHBEs) (1.5 uM DZNep, vehicle PBS; 6h p...
ORGANISM(S): Homo sapiens (Human) 
2022-06-28 | PXD034361 | Pride
GLP-1 agonists are potent glucose-lowering agents, however, their effect on adolescent organisms needs to be clarified Transgenic pigs expressing a dominant-negative GLP receptor randomly assigned for a 90 day treatment trial with liraglutide (0.6-1.8 mg per day)/placebo
ORGANISM(S): Sus scrofa 
Sort   by:  
 Page size